Minirin Nazal Spray 0.1mg/ml 2.5ml Imported

Minirin Nazal Spray 0.1mg/ml 2.5ml Imported works by replacing vasopressin, a hormone that is normally produced in the body to help balance the amount of water and salt.

Side effects

Major & minor side effects for Minirin Nazal Spray 0.1mg/ml 2.5ml Imported

• Nasal congestion
• Headache
• Nosebleed severe
• Sore throat
• Nausea
• Abdominal pain and cramps
• Flushing
• Injection site pain

Uses of Minirin Nazal Spray 0.1mg/ml 2.5ml Imported

What is it prescribed for?

• Diabetes insipidus

  This medicine is used in the treatment of diabetes insipidus, a condition characterized by symptoms such as increased thirst and increased amount of urination.

• Hemophilia A

  The injectable and intranasal forms of this medicine are used to maintain hemostasis in patients suffering from Hemophilia A, a genetic deficiency of a clotting factor, which results in an increased amount of bleeding.

• Von Willebrand Disease

  The injectable and intranasal forms of this medicine are used to maintain hemostasis in patients suffering from Von Willebrand Disease, which is a genetic disorder caused by missing or defective von Willebrand factor (VWF), that may result in an excessive amount of bleeding.

• Bedwetting

  The oral form of this medicine is used in the treatment of bedwetting (primary nocturnal enuresis).

Concerns

When not to use?

• Fluid restriction

  This medicine may lead to water intoxication and/or very low blood sodium levels which may be fatal in some patients. Hence, fluid restriction is recommended during treatment with this medicine, especially when the medicine is not used to control increased urination. Report any symptoms such as a headache, nausea, vomiting, weight gain, restlessness, fatigue, lethargy, disorientation, depressed reflexes, loss of appetite, irritability, muscle weakness, muscle spasms or cramps, hallucinations, decreased levels of consciousness, confusion, etc. to the doctor immediately. Close monitoring of blood sodium levels, appropriate patient/caregiver counseling, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

• Type IIB von Willebrand’s disease

  This medicine is not recommended for use in patients suffering from type IIB Von Willebrand disease due to the increased risk of worsening of the patient's condition. Appropriate diagnostic tests should be done to determine the type of Von Willebrand disease prior to beginning therapy with this medicine. Replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

• Habitual polydipsia (increased thirst)

  This medicine should be used with caution in patients with habitual or psychogenic polydipsia who may be more likely to drink excessive amounts of water, due to the increased risk of water intoxication and decreased blood sodium levels. Close monitoring of blood sodium levels, appropriate patient/caregiver counseling, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

Nasal/Oral forms: Use this medicine exactly as advised by your doctor. Do not use in larger or smaller amounts than advised/prescribed. Consult the doctor if you experience any undesirable side effects. Ensure that the treatment course is completed. Do not stop the use of this medicine without consulting your doctor. Injectable forms: This medicine is generally used prior to a surgical procedure to reduce bleeding in patients suffering from hemophilia A and/or von Willebrand disease. Inform the doctor if you have a known history of an allergy to this medicine. Report to the doctor all your current medications including any herbs and supplements as well as your medical history before undergoing treatment with this medicine.

• Can be taken with or without food, as advised by your doctor
• To be taken as instructed by doctor
• May cause sleepiness

• medlineplus.gov - Desmopressin [Internet]. Available from: https://medlineplus.gov/druginfo/meds/a608010.html [cited 28/7/2020]. 2020